Firma Eckert & Ziegler Strahlen- und Medizintechnik, Autor bei PR-Web

Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates

Posted on 8. January 2024 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged alpha, artbio, cancer, clinical, conrad, eckert, market, new, nuclear, patients, production, prostate, radium, therapy, with

Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply agreement. Under the collaboration Eckert & […]

First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)

Posted on 22. November 2023 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in Research / Development Tagged 68ga, cancer, cell, clinical, cns, cxcr4, eckert, lymphoma, patients, pentixafor, pentixapharm, pentixather, pet, tumor, with

Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today has announced that a first patient has been treated in a dose-finding clinical phase I/II study with Yttrium (90Y) anditixafortide (PentixaTher) at the University […]

Personnel Changes in the Management of Eckert & Ziegler AG. Changes in the Executive Board and Supervisory Board

Posted on 22. November 2023 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged amp, board, clinical, eckert, equity, forum, future, german, management, measures, pentixapharm, ptx, shareholders, supervisory, ziegler

Dr. Hakim Bouterfa, Executive Board member of Eckert & Ziegler AG and responsible for clinical development, will leave the Executive Board of Eckert & Ziegler AG at the end of the year and in future will concentrate exclusively on his […]

Eckert & Ziegler Establishess German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes

Posted on 14. November 202314. November 2023 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged cancer, capital, china, company, construction, diagnostics, eckert, market, medical, pharmaceutical, production, technology, therapy, with, ziegler

Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma). Eckert & Ziegler will benefit from the cooperation […]

Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials

Posted on 23. October 202323. October 2023 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged ablaze, actinium, cancer, cells, clinical, eckert, lutetium, market, patients, radiotherapy, research, security, strong, therapy, with

Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. 177Lu). Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and research activities utilizing Lutetium-177. Ablaze is currently developing […]

Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG

Posted on 20. October 202323. October 2023 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged buyback, cancer, dividend, eckert, forecast, IFRS, market, myelo, pentixapharm, production, report, statements, supervisory, therapy, with

The Executive Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) resolved at its meeting today, with the approval of the Supervisory Board, the strategy and investment priorities for the coming years. In this context the Supervisory Board of Eckert […]

Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients

Posted on 13. September 202313. September 2023 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged bgrt, bone, cancer, illuccix, market, patients, psma, radiotherapy, satellite, scintix, shl, shls, storage, telix, with

Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreement with RefleXion Medical, Inc. (RefleXion) and Telix Pharmaceuticals Limited (ASX:TLX, Telix) to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically […]

Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023

Posted on 10. August 2023 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged amounted, board, currency, eckert, energy, expenses, financial, forecast, future, nuclear, pharmaceutical, report, therapy, with, ziegler

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023. At € 10.9 million or € 0.52 per share, net income was € 3.5 million […]

Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items

Posted on 21. July 202322. July 2023 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged amp, applications, board, currency, decline, eckert, fiscal, forecast, half, medical, pharmaceutical, profit, segment, these, ziegler

First half of 2023: sales of 118.0 million EUR (previous year: 106.8 million EUR) profit of 10.9 million EUR (previous year: 15.4 million EUR) Forecast 2023: sales of just under 230 million EUR (confirmed) profit of around EUR 25 million […]

Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA

Posted on 30. May 2023 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged america, company, connect, devices, eckert, edition, market, medical, players, radiopharmaceuticals, research, solutions, theranostics, with, ziegler

By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of radiopharmaceuticals. On June 1st, 2023, the company will connect potential and existing […]